Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
Hirokazu Ogino, … , Mitchel S. Berger, Hideho Okada
Hirokazu Ogino, … , Mitchel S. Berger, Hideho Okada
Published December 9, 2021
Citation Information: J Clin Invest. 2022;132(3):e151239. https://doi.org/10.1172/JCI151239.
View: Text | PDF
Clinical Research and Public Health Oncology Article has an altmetric score of 10

Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

  • Text
  • PDF
Abstract

BACKGROUND Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy.METHODS We conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor.RESULTS A total of 17 eligible patients were enrolled — 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident–like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination.CONCLUSION The regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies.TRIAL REGISTRATION ClinicalTrials.gov NCT02549833.FUNDING NIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.

Authors

Hirokazu Ogino, Jennie W. Taylor, Takahide Nejo, David Gibson, Payal B. Watchmaker, Kaori Okada, Atsuro Saijo, Meghan R. Tedesco, Anny Shai, Cynthia M. Wong, Jane E. Rabbitt, Michael R. Olin, Christopher L. Moertel, Yasuhiko Nishioka, Andres M. Salazar, Annette M. Molinaro, Joanna J. Phillips, Nicholas A. Butowski, Jennifer L. Clarke, Nancy Ann Oberheim Bush, Shawn L. Hervey-Jumper, Philip Theodosopoulos, Susan M. Chang, Mitchel S. Berger, Hideho Okada

×

Total citations by year

Year: 2025 2024 2023 2022 Total
Citations: 4 10 14 4 32
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (32)

Title and authors Publication Year
Tissue‐resident memory T cells in diseases and therapeutic strategies
Xie D, Lu G, Mai G, Guo Q, Xu G
MedComm 2025
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence
Piyadasa H, Oberlton B, Ribi M, Ranek JS, Averbukh I, Leow K, Amouzgar M, Liu CC, Greenwald NF, McCaffrey EF, Kumar R, Ferrian S, Tsai AG, Filiz F, Fullaway CC, Bosse M, Varra SR, Kong A, Sowers C, Gephart MH, Nuñez-Perez P, Yang E, Travers M, Schachter MJ, Liang S, Santi MR, Bucktrout S, Gherardini PF, Cole K, Barish ME, Brown CE, Oldridge DA, Drake RR, Phillips JJ, Okada H, Prins R, Bendall SC, Angelo M
bioRxiv 2025
A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme
Alkayyal AA, Mahmoud AB
Pharmaceuticals 2025
Oligodendroglioma: Advances in Molecular Mechanisms and Immunotherapeutic Strategies
Zhao Y, Yu Y, Chen W, Zhang X, Lv J, Zhao H
Biomedicines 2025
Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles
Zhou Y, Liu M, Huang X, Liu Z, Sun Y, Wang M, Huang T, Wang X, Chen L, Jiang X
Frontiers in Oncology 2024
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy
Stepanenko AA, Sosnovtseva AO, Valikhov MP, Chernysheva AA, Abramova OV, Naumenko VA, Chekhonin VP
Frontiers in immunology 2024
Systemic and local immunosuppression in glioblastoma and its prognostic significance.
Stepanenko AA, Sosnovtseva AO, Valikhov MP, Chernysheva AA, Abramova OV, Pavlov KA, Chekhonin VP
Frontiers in immunology 2024
TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis.
Qiu L, Ji H, Wang K, Liu W, Huang Q, Pan X, Ye H, Li Z, Chen G, Xing X, Dong X, Tang R, Xu H, Liu J, Cai Z, Liu X
EMBO Molecular Medicine 2024
Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives.
Ren D, Xiong S, Ren Y, Yang X, Zhao X, Jin J, Xu M, Liang T, Guo L, Weng L
Computational and Structural Biotechnology Journal 2024
Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer
Rahman MM, Grice ID, Ulett GC, Wei MQ
Journal of Immunology Research 2024
Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas?
Phung LH, Nejo T, Okada H
Vaccines 2024
Oligodendroglioma patient survival is associated with circulating B-cells and age
Taylor JW, Warrier G, Hansen HM, McCoy L, Rice T, Guerra G, Francis SS, Clarke JL, Bracci PM, Hadad S, Kelsey KT, Wrensch M, Molinaro AM, Wiencke JK
Neuro-Oncology Advances 2024
Spermine Synthase : A Potential Prognostic Marker for Lower-Grade Gliomas
Liu C, Li H, Hu X, Yan M, Fu Z, Zhang H, Wang Y, Du N
Journal of Korean Neurosurgical Society 2024
Vaccines for cancer prevention: exploring opportunities and navigating challenges.
Graciotti M, Kandalaft LE
Nature reviews. Drug discovery 2024
Therapeutic Vaccination for HPV-Mediated Cancers
Yan F, Cowell LG, Tomkies A, Day AT
Current Otorhinolaryngology Reports 2023
The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches
Kalluri AL, Shah PP, Lim M
International journal of molecular sciences 2023
Enhanced in vivo anti-tumor efficacy of whole tumor lysate in combination with whole tumor cell-specific polyclonal antibody
Rahimmanesh I, Esmaili Y, Ghafouri E, Hejazi SH, Khanahmad H
Research in Pharmaceutical Sciences 2023
Immunotherapy associated central nervous system complications in primary brain tumors
Mantica M, Drappatz J
Frontiers in Oncology 2023
Novel strategies for cancer immunotherapy: counter-immunoediting therapy.
Liu S, Sun Q, Ren X
Journal of Hematology & Oncology 2023
Implications of CRNDE in prognosis, tumor immunity, and therapeutic sensitivity in low grade glioma patients.
Yang C, Jiang Y, Hu F, Li Q, Qi B
Cancer Cell International 2023
Immunotherapy for Recurrent Glioma—From Bench to Bedside
Pu Y, Zhou G, Zhao K, Chen Y, Shen S
Cancers 2023
Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H
Cancers 2023
Impact of propofol versus sevoflurane anesthesia on molecular subtypes and immune checkpoints of glioma during surgery
Cen S, Yang G, Bao H, Yu Z, Liang L
2023
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients
Faisal SM, Castro MG, Lowenstein PR
Molecular Therapy 2023
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements
Agosti E, Zeppieri M, De Maria L, Tedeschi C, Fontanella MM, Panciani PP, Ius T
International journal of molecular sciences 2023
Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy.
Song KW, Scott BJ, Lee EQ
Current Neurology and Neuroscience Reports 2023
Tumor vaccines: Toward multidimensional anti-tumor therapies
Tan Y, Chen H, Gou X, Fan Q, Chen J
Human Vaccines & Immunotherapeutics 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas
Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H
Neuro-Oncology 2023
The future of cancer immunotherapy for brain tumors: a collaborative workshop
C Brown, S Bucktrout, L Butterfield, O Futer, E Galanis, A Hormigo, M Lim, H Okada, R Prins, S Marr, K Tanner
Journal of Translational Medicine 2022
Research progress of anti-glioma chemotherapeutic drugs (Review)
Y Zhou, W Wang, N Chen, L Wang, J Huang
Oncology reports 2022
Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
Tan S, Spear R, Zhao J, Sun X, Wang P
Frontiers in Genetics 2022
Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
Zhou J, Li L, Jia M, Liao Q, Peng G, Luo G, Zhou Y
Cancer Medicine 2022

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Posted by 2 X users
79 readers on Mendeley
See more details